INVO Bioscience (INVO) Misses Q1 EPS by 8c, Revenues Beat

Go back to INVO Bioscience (INVO) Misses Q1 EPS by 8c, Revenues Beat

INVO Bioscience Reports First Quarter 2021 Financial and Operating Results and Provides Business Update

May 17, 2021 4:05 PM EDT

SARASOTA, Fla., May 17, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, today announced financial results for the first quarter of 2021 ended March 31, 2021 and provides a business update.

... More